CA
NZ
UK
AU
IND
US
Vaxxinity is a biotechnology company that built a platform aimed at turning chronic-disease treatment toward vaccine-like immunotherapies, historically targeting neurodegenerative conditions such as Parkinson's and Alzheimer's disease. The pivotal corporate development for the stock came in April 2024, when Vaxxinity announced its intention to …
On September 10, 2025, MEI Pharma announced it had rebranded as Lite Strategy, Inc. and adopted the newNasdaqticker LITS. The move accompanied a strategic overhaul: the company closed a $100 million private placement in July 2025 to fund a digital-asset treasury built around Litecoin …
Biomolecular Life Holdings is a small over-the-counter company positioning itself in the wellness and longevity space,Marketingpremium supplements it describes as developed using nutrigenomics and artificial intelligence, alongside services spanning precision nutrition and regenerative wellness technologies. The corporate history matters here: the entity traces back …
TScan Therapeutics is a Nasdaq-listed, clinical-stage biotechnology company developing T-cell receptor-engineered (TCR-T) cell therapies for cancer and other diseases. On September 2, 2026, TScan announced a strategic reorganization to concentrate on in vivo-engineered TCR-T therapy for solid tumors. The plan advances two candidates targeting …
Heron Therapeutics is a Nasdaq-listed commercial-stage pharmaceutical company built around its proprietary Biochronomer drug-delivery technology. Its portfolio spans acute-care and oncology-supportive products, including ZYNRELEF and APONVIE in acute care and CINVANTI and SUSTOL in the oncology-supportive space. The pivotal recent development came on June …
Zivo Bioscience develops therapeutic and nutritional products derived from proprietary algal cultures, targeting animal health, human health and dietary-supplement markets. Its intellectual property centers on proprietary algal strains and patented production techniques. A notable structural development came in May 2026, when the company transitioned …
Atossa Therapeutics is a Nasdaq-listed, clinical-stage biopharmaceutical company focused on breast cancer. Its lead asset is (Z)-endoxifen, an oral selective estrogen receptor modulator and degrader in Phase 2 development for breast-cancer treatment and risk reduction, with exploration in additional therapeutic areas. Through 2026 the …
BNB Plus Corp. is the rebranded successor to Applied DNA Sciences, a change unveiled in late 2025 as management pivoted toward a digital-asset treasury model centred on the BNB token. Crucially, the company did not abandon its scientific roots: it retains a biopharmaceutical and …
Trinity Biotech, headquartered in Ireland and listed on Nasdaq, develops and markets medical diagnostic products spanning clinical-laboratory and point-of-care testing, including assays for infectious diseases, sexually transmitted infections and diabetes monitoring. In a striking diversification, the company has launched Trinovium, a subsidiary focused on …
Accendra Health began trading on the New York Stock Exchange under the ticker ACH on January 2, 2026, after its predecessor, Owens & Minor, sold its Products & Healthcare Services distributionBusinessand the Owens & MinorBrandon December 31, 2025. What remained, the home-based care operation …
Please wait processing your request...